胃と腸42巻8号

2007年07月発行

今月の主題 胃MALTリンパ腫―除菌無効例の特徴と治療戦略

主題

除菌無効胃MALTリンパ腫の治療―化学療法を中心に

著者： 渡部則彦¹ 岩野昌宏¹ 西尾彰功¹ 近藤忠一² 千葉勉¹

所属機関： ¹京都大学大学院医学研究科消化器内科学 ²京都大学大学院医学研究科血液腫瘍内科学

ページ範囲：P.1241 - P.1249

文献概要

要旨　Helicobacter pylori感染は，胃MALTリンパ腫の病態形成に深く関与しており，その除菌療法は，胃MALTリンパ腫治療の第一選択と位置づけられている．除菌療法が無効な症例に対する二次治療として，放射線療法は確立されつつあるが，化学療法については，その有用性は示唆されてはいるものの確立されるに至っていない．近年盛んに用いられている抗CD20抗体，rituximabは，従来のリンパ腫に対する標準的化学療法に併用することでその治療成績を向上させることが示されており，MALTリンパ腫を含む低悪性度リンパ腫の治療でも用いられつつある．これらのことから，胃MALTリンパ腫の除菌無効例の二次治療としても，rituximabを併用した化学療法が非常に有望視されている．

参考文献

1) Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1983

2) Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 128:1579-1605, 2005

3) Isaacson PG, Du M-Q. Gastrointestinal lymphoma:Where morphology meets molecular biology. J Pathol 205:255-274, 2005

4) Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach:a review of treatment options. Int J Radiat Oncol Biol Phys 46:1093-1103, 2000

5) Montalban C, Norman F. Treatment of gastric mucosa-associated lymphoid tissue lymphoma:Helicobacter pylori eradication and beyond. Expert Rev Anticancer Ther 6:361-371, 2006

6) Inagaki H, Nakamura T, Li C, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 28:1560-1567, 2004

7) Iwano M, Watanabe N, Matsushima Y, et al. Rapid development of diffuse large B-cell lymphoma after successful eradication of Helicobacter pylori for gastric MALT lymphoma. Am J Gastroenterol 101:2878-2883, 2006

8) Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16:1916-1921, 1998

9) Saga K, Fukui T, Kato Y, et al. Localized cytomegalovirus reactivation after radiotherapy for high-grade gastric lymphoma. Gastrointest Endosc 65:545-547, 2007

10)紀藤毅，山村義孝．胃悪性リンパ腫の治療;外科的治療を中心に．消化器外科 16:1339-1407, 1993

11)大花正也，岡野明浩，松下光伸，他．胃悪性リンパ腫の予後因子および外科的切除の重要性について．日消誌 91:241-249, 1994

12)佐野武，笹子三津留，丸山圭一，他．胃悪性リンパ腫の外科治療．消化器外科 18:1239-1243, 1995

13) Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma:II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 19:3874-3883, 2001

14) Yoon SS, Coit DG, Portlock CS, et al. The diminishing role of surgery in the treatment of gastric lymphoma.　Ann Surg 240:28-37, 2004

15) Tondini C, Balzarotti M, Santoro A, et al. Initial chemotherapy for primary resectable large-cell lymphoma of the stomach.　Ann Oncol 8:497-499, 1997

16) Raderer M, Valencak J, Osterreicher C, et al. Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor Stages IE and IIE. Cancer 88:1979-1985, 2000

17) Liu HT, Hsu C, Chen CL, et al. Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. Am J Hematol 64:175-179, 2000

18) Binn M, Ruskone-Fourmestraux A, Lepage E, et al. Surgical resection plus chemotherapy versus chemotherapy alone:comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol 14:1751-1757, 2003

19) Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998

20) Ishikura S, Tobinai K, Ohtsu A, et al. Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci 96:349-352, 2005

21) Montalban C, Castrillo JM, Abraira V, et al. Gastric B-cell mucosa-associated lymphoid tissue(MALT)lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol 6:355-362, 1995

22) Thieblemont C, Dumontet C, Saad H, et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma:a retrospective study of patients treated during 1976-2001. Leuk Lymphoma 44:257-262, 2003

23) Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 26:527-537, 1997

24) Aviles A, Neri N, Nambo MJ, et al. Mucosa-associated lymphoid tissue(MALT)lymphoma of the stomach:results of a controlled clinical trial. Med Oncol 22:57-62, 2005

25) Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 13:2524-2529, 1995

26) Wohrer S, Drach J, Hejna M, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue(MALT lymphoma)with mitoxantrone, chlorambucil and prednisone(MCP). Ann Oncol 14:1758-1761, 2003

27) Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine:a phase II study. J Clin Oncol 20:3872-3877, 2002

28) Raderer M, Wohrer S, Bartsch R, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23:8442-8446, 2005

29) Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002

30) Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999

31) Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65:306-310, 2003

32) Connoni A, Martinelli G, Thueblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102:2741-2745, 2003

33) Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23:1979-1983, 2005

34) Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 70:411-417, 2006